CGON shares are rising as cretostimogene approaches a planned 2026 BLA filing, supported by encouraging Phase II data. The company also reiterated liquidity strength, maintaining a cash position expected to fund operations through 2029, reducing near-term financing risk.
CGON shares are rising as cretostimogene approaches a planned 2026 BLA filing, supported by encouraging Phase II data. The company also reiterated liquidity strength, maintaining a cash position expected to fund operations through 2029, reducing near-term financing risk.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
